Induction of cyclooxygenase-2 on activated T lymphocytes: Regulation of T cell activation by cyclooxygenase-2 inhibitors

Journal of Immunology

Volumn 163, Issue 1, 1999, Pages 111-119

  Iñiguez, Miguel A ^a   Punzón, Carmen ^a   Fresno, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR FACTOR; PROSTAGLANDIN; PROTEIN SYNTHESIS INHIBITOR; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CELL PROLIFERATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELLS, CULTURED; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; CYTOKINES; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HUMANS; ISOENZYMES; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; PROMOTER REGIONS (GENETICS); PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; T-LYMPHOCYTES; TRANSCRIPTION, GENETIC;

EID: 0242478343     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Ullman, K. S., J. P. Northrop, C. L. Verweij, and G. R. Crabtree. 1990. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu. Rev. Immunol. 8:421.
2. Weiss, A., and D. R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. Cell 76:263.
3. Altman, A., K. M. Coggeshall, and T. Mustelin. 1990. Molecular events mediating T cell activation. Adv. Immunol. 48:227.
4. Harris, E. D., Jr. 1990. Rheumatoid arthritis, pathophysiology and implications for therapy. N. Engl. J. Med. 322:1277.
5. Feldmann, M., F. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14:397.
6. Moulton, P. J. 1996. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br. J. Biomed. Sci. 53:317.
7. Samuelson, B., M. Goldyne, E. Granström, M. Hamberg, S. Hammarström, and C. Malmsten. 1978. Prostaglandins and thromboxanes. Annu. Rev. Biochem. 47: 997.
8. Hammarström, S. 1983. Leukotrienes. Annu. Rev. Biochem. 52:355.
9. Kurland, J. I., and R. Bockman. 1978. Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J. Exp. Med. 147:952.
10. Kennedy, M. S., J. D. Stobo, and M. E. Goldyne. 1980. In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins 20:135.
11. Goodwin, J. S. 1989. Immunomodulation by eicosanoids and anti-inflammatory drugs. Curr. Opin. Immunol. 3:295.
12. Della Bella, S., M. Molteni, S. Compasso, C. Zulian, M. Vanoli, and R. Scorza. 1997. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukotrienes Essent, Fatty Acids 56:177.
13. Kumar, G. S., and U. N. Das. 1994. Effect of prostaglandins and their precursor on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins,. Prostaglandins Leukotrienes Essent, Fatty Acids 50:331.
14. Phipps, R. P., S. H. Stein, and R. L. Roper. 1991. A new view of prostaglandin E regulation of the immune response. Immunol. Today 12:349.
15. Smith, W. L., and D. L. DeWitt. 1996. Prostaglandin endoperoxide H synthase-1 and -2. Adv. Immunol. 62:167.
16. Griswold, D. E., and J. L. Adams. 1996. Constitutive cyclooxygenase (Cox-1) and inducible cyclooxygenase (Cox-2): rationale for selective inhibition and progress to date. Med. Res. Rev. 16:181.
17. Herschman, H. R. 1996. Prostaglandin synthase 2. Biochim. Biophys. Acta 1299: 125.
18. Jouzeau, J.-Y., B. Terlain, A. Abid, E. Nédélec, and P. Netter. 1997. Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563.
19. Penning, T. D., J. J. Talley, S. R. Bertenshaw, J. S. Carter, P. W. Collins, S. Docter, M. J. Graneto, L. F. Lee, J. W. Malecha, J. M. Miyashiro, et al. 1997. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J. Med. Chem. 40: 1347.
20. Futaki, N., I. Arai, Y. Hamasaka, S. Takahashi, S. Higuchi, and S. Otomo. 1993. Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation. J. Pharm. Pharmacol. 45:753.
21. Engelhardt, G., D. Homma, K. Schlegel, R. Utzmann, and C. Schnitzler. 1995. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favorable gastrointestinal tolerance. Inflamm. Res. 44:423.
22. Koop, E., and S. Ghosh. 1994. Inhibition of NF-κB by sodium salycilate and aspirin. Science 265:956.
23. Hall, V. C., and R. E. Wolf. 1997. Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis. J. Rheumatol. 24:1467.
24. Dolhain, R. J. E. M., P. DeKuiper, C. L. Yerweis, J. M. A. Penders, F. C. Breedveld, B. A. C. Dijkmans, and A. M. M. Miltenburg. 1995. Tenidap, but not nonsteroidal anti-inflammatory drugs, inhibits T-cell proliferation and cytokine induction. Scand. J. Immunol. 42:686.
25. Zhou, L., D. Ritchie, E. Y. Wang, A. G. Barbone, D Argentier, and C. Y. Lau. 1994. Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. J. Immunol. 153:5026.
26. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82.
27. Lehman, J. M., J. M. Lenhard, B. B. Olier, G. M. Ringold, and S. A. Kliewer. 1997. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272: 3406.
28. Pimentel-Muiños, F. X., M. A. Muñoz-Fernández, and M. Fresno. 1994. Control of T lymphocyte activation and interleukin-2 receptor expression by endogenously secreted lymphokines. J. Immunol. 152:5714.
29. Iñiguez, M., J. Pablos, P. Carreira, F. Cabré, and J. Gomez-Reino. 1998. Detection of Cox-1 and Cox-2 isoforms in synovial fluid cells from inflammatory joint diseases. Br. J. Rheumatol. 37:773.
30. Sambrook, J., E. Fritsch, and T. Maniatis. 1989. Molecular Cloning. A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
31. Morte, B., M. Iñiguez, P. Lorenzo, and J. Bernal. 1997. Thyroid hormone-regulated expression of RC3/neurogranin in the immortalized hypothalamic cell line GT1-7. J. Neurochem. 69:902.
32. 2-microglobulin enhancers. EMBO J. 6:3317.
33. Rhoades, K. L., S. H. Golub, and J. Economou. 1992. The regulation of the human tumor necrosis factor α promoter region in macrophage, T cell, and B cell lines. J. Biol. Chem. 267:22102.
34. Durand, D. B., S. J.-P., M. R. Bush, R. E. Peplogle, R. Belagaje, and G. R. Crabtree. 1988. Characterization of antigen receptor response elements within the interleukin-2-enhancer. Mol. Cell. Biol. 8:1715.
35. Nordeen, S. K. 1988. Luciferase reporter gene vectors for analysis of promoter and enhancers. Biotechniques 6:454.
36. Truneh, A., F. Albert, P. Golstein, and A. M. Schmitt-Verhulst. 1985. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313:318.
37. Linsley, P. S., and J. A. Ledbetter. 1993. The role of the CD28 receptor during T cell responses to antigen. Anna. Rev. Immunol. 11:191.
38. Quesniaux, V. F. J. 1993. Immunosuppressants: tools to investigate the physiological role of cytokines. Bioessays 15:731.
39. Schreiber, S. L., and G. R. Crabtree. 1992. The mechanism of action of cyclosporin A and FK506. Immunol. Today 13:136.
40. Ryseck, R., C. Raynoschek, K. MacDonald-Bravo, K. Dorfman, and R. Bravo. 1992. Identification of an immediate early gene, PGHS-b, whose protein product has prostaglandin synthase/cyclooxygenase activity. Cell Growth Differ. 3:443.
41. Herschmann, H. R. 1991. Primary response genes induced by growth factors and tumor promoters. Annu. Rev. Biochem. 60:281.
42. Mitchell, J. A., P. Akarasereenont, C. Thiemermann, R. J. Flower, and J. R. Vane. 1993. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc. Natl. Acad. Sci. USA 90:11693.
43. Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi, and S. Otomo. 1994. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47:55.
44. Goldyne, M. E. 1989. Eicosanoid metabolism by lymphocytes: do all human nucleated cells generate eicosanoids? Pharmacol. Res. 21:241.
45. Goldyne, M. E. 1988. Lymphocytes and arachidonic acid metabolism. Prog. Allergy 44:140.
46. Maier, J. A., T. Hla, and T. Maciag. 1990. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J. Biol. Chem. 265: 10805.
47. Furue, M., S. I. Katz, Y. Kawakami, and T. Kawakami. 1990. Coordinate expression of src family protooncogenes in T cell activation and its modulation by cyclosporine. J. Immunol. 144:736.
48. Martin, M., D. Neumann, T. Hoff, K. Resch, D. L. DeWitt, and S. M. Goppelt. 1994. Interleukin-1-induced cyclooxygenase 2 expression is suppressed by cyclosporin A in rat mesangial cells. Kidney Int. 45:150.
49. Griswold, D., and J. Adams. 1996. Constitutive cyclooxygenase (Cox-1) and inducible cyclooxygenase (Cox-2): rationale for selective inhibition and progress to date. Med. Res. Rev. 16:181.
50. Cadroy, Y., D. Dupouy, and B. Boneu. 1998. Arachidonic acid enhances the tissue factor expression of mononuclear cells by the cyclo-oxygenase-1 pathway: beneficial effect of n-3 fatty acids. J. Immunol. 160:6145.
51. Meade, E., W. Smith, and D. DeWitt. 1993. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J. Biol. Chem. 268:6610.
52. Masferrer, J. L., B. S. Zweifel, K. Seibert, and P. Needleman. 1990. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J. Clin. Invest. 86:1375.
53. O'Banion, M. K., V. D. Winn, and D. A. Young. 1992. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA 89:4888.
54. Zhou, L., B. L. Pope, E Chourmouzis, L. W. P. Fung, and C. Y. Lau. 1996. Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. Eur. J. Immunol. 26:120.
55. Kazmi, S. M. I., R. K. Plante, V. Visconti, G. R. Taylor, L. Zhou, and C. Y. Lau. 1995. Suppression of NFxB activation and NFκB-dependent gene expression by Tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. J. Cell. Biochem. 57:299.
56. Griswold, D. E., L. M. Hillegass, J. J. Breton, K. M. Esser, and J. L. Adams. 1993. Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive antiinflammatory drugs and other pharmacological classes using mouse tumor necrosis factor a production. Drugs Exp. Clin. Res. 19:243.
57. Pouliot, M., J. Baillargeon, J. C. Lee, L. G. Cleland, and M. J. James. 1997. Inhibition of prostaglandin endoperoxide synthase-2 expression in stimulated human monocytes by inhibitors of p38 mitogen-aclivated protein kinase. J. Immunol. 158:4930.
58. Jain, J., C. Lom, and A. Rao. 1995. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7:333.
59. Penix, L., W. M. Weaver, Y. Pang, H. A. Young, and C. B. Wilson. 1993. Two essential regulatory elements in the human interferon γ promoter confer activa-tion specific expression in T cells. J. Exp. Med. 178:1483.
60. Rao, A., C. Luo, and P. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. Anna. Rev. Immunol. 15:707.
61. Pimentel-Muiños, F., J. Mazana, and M. Fresno. 1995. Biphasic control of nuclear factor-κB activation by the T cell receptor complex: role of tumor necrosis factor α. Eur. J. Immunol. 25:179.
62. Monta, I., M. Schindler, M. K. Regier, J. C. Otto, T. Hori, D. L. DeWitt, and W. L. Smith. 1995. Different intracellular locations for prostaglandin endoperoxide H synthases-1 and -2. J. Biol. Chem. 270:10902.
63. 4 pathway to inflammation control. Nature 384:39.
64. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 391:79.
65. 1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res. 56:733.
66. Tsuji, M., S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R. DuBois. 1998. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93: 705.
67. Tsujii, M., and R. N. DuBois. 1995. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493.
68. Munroe, D. G., E. Y. Wang, J. P. MacIntyre, S. S. Tam, D. H. Lee, G. R. Taylor, L. Zhou, R. K. Plante, S. M. Kazmi, and P. A. Bauerle. 1995. Novel intracellular signalling function of prostaglandin H synthase-1 in NF-κB activation. J. Inflamm. 45:260.
69. Yin, M.-J., Y. Yamamoto, and R. Gaynor. 1998. The anti-inflammatory agents aspirin and salycilate inhibit the activity of IκB kinase-β. Nature 396:77.